Abstract
Whooping cough is a highly contagious respiratory disease caused by Bordetella pertussis. Despite widespread vaccination, its incidence has been rising alarmingly, and yet, the physiology of B. pertussis remains poorly understood. We combined genome-scale metabolic reconstruction, a novel optimization algorithm, and experimental data to probe the full metabolic potential of this pathogen, using B. pertussis strain Tohama I as a reference. Experimental validation showed that B. pertussis secretes a significant proportion of nitrogen as arginine and purine nucleosides, which may contribute to modulation of the host response. We also found that B. pertussis can be unexpectedly versatile, being able to metabolize many compounds while displaying minimal nutrient requirements. It can grow without cysteine, using inorganic sulfur sources, such as thiosulfate, and it can grow on organic acids, such as citrate or lactate, as sole carbon sources, providing in vivo demonstration that its tricarboxylic acid (TCA) cycle is functional. Although the metabolic reconstruction of eight additional strains indicates that the structural genes underlying this metabolic flexibility are widespread, experimental validation suggests a role of strain-specific regulatory mechanisms in shaping metabolic capabilities. Among five alternative strains tested, three strains were shown to grow on substrate combinations requiring a functional TCA cycle, but only one strain could use thiosulfate. Finally, the metabolic model was used to rationally design growth media with > 2-fold improvements in pertussis toxin production. This study thus provides novel insights into B. pertussis physiology and highlights the potential, but also the limitations, of models based solely on metabolic gene content.
Original language | English |
---|---|
Journal | Applied and Environmental Microbiology |
Volume | 83 |
Issue number | 21 |
DOIs | |
Publication status | Published - 1 Nov 2017 |
Funding
This work was sponsored by GlaxoSmithKline Biologicals S.A., which provided the funding source, was involved in all stages of the study conduct and analysis, and took charge of the costs incurred in publishing. Additional support came from the VU University Amsterdam through the Amsterdam Institute for Molecules, Medicines and Systems (to J.B., P.K., and M.G.), and from ZonMW through Zenith grant 93511039 (to B.G.O.). F.B.D.S. is supported by the Netherlands Organization for Scientific Research (NWO) through VENI grant 863.11.019. The additional funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. GSK acknowledges Marjolein van Gent (RIVM, The Netherlands) for the kind gift of strains B1917, B1920, B1831, and B1834. P.G., P.D.R., V.S., and P.D. acknowledge the LaSo team of GSK for preparing culture media, the bacterial preclinical immunology group, and in-process Pa quality control (QC) team for PT quantification, as well as Angelo Morreale, Karim Donnay, and Blandine David for technical advice and expert technical assistance. P.G. warmly thanks L. Fontaine for critically reading the manuscript. P.D.R., V.S., P.D., and P.G. are, or were at the time of study, employees of the GSK group of companies. P.D. reports ownership of shares in GSK. P.G., P.D., F.B.D.S. and B.T. are named inventors on patent applications relating to metabolic modeling and to chemically defined media (UK patent application GB1322303.7 and PCT application PCT/IB2014/064428, published as WO2015/092650). P.G., F.B.D.S., B.T., and P.D. conceived the study. P.G. and F.B.D.S. designed the experiments. F.B.D.S., B.T., and P.G. constructed the metabolic model. F.B.D.S. developed the EMAF algorithm with B.G.O. and G.W.K. and FiJo with J.B. P.D.R., V.S., F.B.D.S., P.G., P.K., and M.G. performed the experiments. P.G., F.B.D.S., and B.T. analyzed the data and wrote the manuscript.
Funders | Funder number |
---|---|
Amsterdam Institute for Molecules, Medicines and Systems | |
F.B.D.S. | |
GlaxoSmithKline Biologicals S.A. | |
Netherlands Organization for Scientific Research | |
ZonMw | 93511039 |
Vrije Universiteit Amsterdam | |
GlaxoSmithKline foundation | B1920, QC, B1834, WO2015/092650, PCT/IB2014/064428, B1831 |
Nederlandse Organisatie voor Wetenschappelijk Onderzoek | 863.11.019 |
Keywords
- Bordetella pertussis
- Constraint-based modeling
- Genome-scale metabolic model
- Rational medium design
- Vaccine production
- Whooping cough